Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.

导出 OA

翻译打印收藏纠错

第一作者： Sabela,Bobillo

第一单位： Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.;Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; and.

作者： Sabela,Bobillo ^[1] ; Erel,Joffe ^[2] ; Jessica A,Lavery ^[3] ; David,Sermer ^[2] ; Paola,Ghione ^[2] ; Ariela,Noy ^[2] ; Philip C,Caron ^[2] ; Audrey,Hamilton ^[2] ; Paul A,Hamlin ^[2] ; Steven M,Horwitz ^[2] ; Anita,Kumar ^[2] ; Matthew J,Matasar ^[2] ; Alison,Moskowitz ^[2] ; Collette N,Owens ^[2] ; M Lia,Palomba ^[2] ; Connie L,Batlevi ^[2] ; David,Straus ^[2] ; Gottfried,von Keudell ^[2] ; Andrew D,Zelenetz ^[2] ; Joachim,Yahalom ^[4] ; Ahmet,Dogan ^[5] ; Venkatraman E,Seshan ^[3] ; Anas,Younes ^[2]

作者单位： Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.;Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; and. ^[1] Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. ^[2] Department of Epidemiology and Biostatistics. ^[3] Department of Radiation Oncology, and. ^[4] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. ^[5]